Mohammad Askar

Glaucoma · Surgery

Glaucoma surgery

From aqueous outflow and target pressure to procedure selection, evidence appraisal and postoperative care.

Clinical lectureEnglishApproximately 20 minutesMedical review: 1 October 2026 · 22:28 CEST (Europe/Berlin)Published: 1 October 2026

01From target pressure to procedure selection

Glaucoma surgery aims to preserve remaining vision by lowering intraocular pressure (IOP); it cannot restore established optic-nerve damage. Start with the question: which pressure does this nerve need for stability, and which procedure can reach it at an acceptable risk? IOP is a modifiable treatment target, but visual-field progression, vision, quality of life and treatment burden also determine success. 1 5

The idea guiding this lecture

Start with the pressure the eye needs, then identify the mechanism preventing it. A newer procedure name does not determine suitability.

Assessment and timing

Document glaucoma subtype, angle by gonioscopy, visual field, optic nerve/OCT, rate of progression, baseline and treated IOP, corneal factors, fellow-eye function, lens status, conjunctiva and prior operations. Include medication tolerance, adherence, patient preference and ability to attend follow-up. Surgery may be appropriate when medication/laser is unlikely to preserve sight; exhausting every drop is not a prerequisite. For advanced disease TAGS supports discussing primary trabeculectomy, rather than imposing a rigid last-resort ladder. 1 5

Individual target pressure

Set and reassess a target for each eye, accounting for damage, progression, remaining lifetime, starting pressure and treatment risk. An advanced eye may need a substantially lower pressure than a mildly affected eye. Neither <15 mmHg nor a single stage threshold is a universal prescription; progression despite reaching the current target requires reassessment. 1

02Understand aqueous drainage before choosing the intervention

Conventional aqueous outflow passes through the trabecular meshwork, Schlemm’s canal and collector channels to the venous circulation. Unconventional outflow includes the uveoscleral pathway. Resistance is distributed, including the juxtacanalicular/inner-wall region and distal pathways. Opening the meshwork alone therefore does not guarantee a very low pressure in every eye. 18

Teaching estimates of 80–95% conventional and 5–20% uveoscleral flow, or 75% resistance at the meshwork, are not individual patient constants. Johnstone’s model proposes a mechanical, pulsatile component of drainage supported by experimental observations; it does not establish clinical superiority of a particular operation. 18 19

ProcedureTargetClinical principleRemember
SLTTrabecular meshworkMay reduce drops in suitable populationsSubtype, angle and required pressure
Trabectome · KDB · BANG · GATTOpening/removing trabecular tissueReduces resistance but depends on distal outflowHyphema and remaining pressure; techniques are not automatically equivalent
iStent inject · HydrusBypass meshwork/support Schlemm’s canalComparative evidence versus phaco alone in selected patientsDoes not automatically replace surgery for a very low target
XEN · PreserFloSubconjunctival drainageFiltration bleb with wound-healing managementFibrosis, hypotony, leak and infection
TrabeculectomySubconjunctival filtration routeImportant for low pressure and advanced diseaseHealing and follow-up determine outcomes
Drainage tubesTube to a plateImportant in some scarred/high-risk eyesPressure, cornea and hypotony trade-offs
CyclophotocoagulationReduced aqueous productionSelect by technique and visual potentialInflammation, hypotony, vision loss and retreatment

03When is laser a suitable step?

Selective laser trabeculoplasty (SLT) can be offered as a suitable initial option to selected patients with open-angle glaucoma or ocular hypertension. It can reduce dependence on daily drop administration, but suitability depends on glaucoma subtype, angle and required pressure. 4

In the UK LiGHT trial,69.8% of eyes initially treated with SLT remained at target without drops or incisional surgery after 6 years. Progression was 19.6% versus 26.8% with initial drops. EQ-5 D,GUI and GQL-15 did not differ significantly, whereas GSS symptom scores favoured SLT. These results support long-term disease control, not superiority on every quality-of-life measure. 4

Permitted treatment crossover after 3 years and retention of 73% of original participants limit a pure six-year comparison. These findings alone do not establish superior 24-hour stability or lifetime savings in every health system. 4

Clinical evidence LiGHT,6 y 4

Question and population: InitialSLT/drops; treatment-naïve OAG/OHT

Result: Progression 19.6%/26.8%; trabeculectomy 13/32 eyes; no significant EQ-5 D/GUI/GQL-15 difference.

How should we read it?: 73% original-participant retention; crossover; not all glaucoma.

04Trabecular MIGS: opening or bypassing the meshwork?

MIGS includes different techniques: understand the target tissue and the comparator against which a procedure was tested, rather than treating the label as a single operation.

Trabecular tissue procedures

These procedures reduce resistance at the trabecular meshwork but still depend on the canal and distal drainage. Trabectome ablates tissue electrosurgically, and Kahook Dual Blade (KDB) excises a strip. GATT opens the trabecular wall using a suture or catheter around Schlemm’s canal, potentially over 360°. 12 18

Bent ab-interno needle goniotomy (BANG) uses the needle mechanically; it should not be conflated with a cautery technique because of similar abbreviations. The 2026 randomized trial used 23 G. Hyphema, pressure spikes and failure to reach target remain important; instrument simplicity does not establish equivalence to KDB or zero total cost. 12

Clinical evidence BANG/GATT,24 mo 12

Question and population: 22/23 eyes in 34 patients; pseudophakic mild/moderate POAG

Result: IOP reduction 16.0%/22.44%; medication-free 2/11 eyes; complete success 4.5%/55.0%.

How should we read it?: Small; examiner unmasked; endpoint retention 19/22 and 17/23. Abstract qualified success 11.4% versus body 13.6% for BANG: unresolved reporting discrepancy; not a KDB trial.

Trabecular bypass implants

iStent inject places two bypass stents; Hydrus is an 8 mm canal scaffold spanning about 90°. They act on conventional outflow and depend on downstream function. Segmental drainage is a mechanistic rationale, not a measured guarantee that two stents find a functional collector. The pivotal trials compared device+phaco with phaco alone in selected mild/moderate POAG; they do not prove equivalence to trabeculectomy or superiority among all devices. 10 11

Clinical evidence HORIZON,5 y 10

Question and population: Phaco+Hydrus/phaco alone; selected mild/moderate POAG

Result: IOP≤18 without medication 49.5%/33.8%,p=.003; medication-free 66%/46%; mean medication 0.5/0.9.

How should we read it?: 80%5-year follow-up; phaco comparator; not advanced disease or trab comparison.

Clinical evidence iStent inject,2 y 11

Question and population: Phaco+two stents/phaco;505 eyes(387/118)

Result: ≥20%unmedicated diurnal IOP reduction 75.8%/61.9%,p=.005; reduction 7.0/5.4 mmHg.

How should we read it?: Surrogate outcome and selected phaco population; not proof of optic-nerve recovery.

CyPass and endothelial surveillance

CyPass was a supraciliary/suprachoroidal implant recalled in 2018 after a long-term endothelial-cell-loss signal. This device-specific finding must not be assigned to every angle implant. 16

Examine implant position and corneal status; endothelial assessment depends on the device, examination and risk. The evidence presented here does not support a uniform annual schedule for all MIGS. Existing CyPass implants need specialist device-specific follow-up, not automatic removal.

05Subconjunctival filtration and conventional surgery

Subconjunctival bleb surgery

XEN drains to the subconjunctival space, commonly by an ab-interno route; PreserFlo is placed ab externo. These are bleb-forming procedures (often called MIBS), not simply interchangeable with trabecular MIGS. MMC and subsequent wound-healing intervention are commonly used, with local/off-label considerations; needling is possible rather than inevitable. Scarring, hypotony, leak, infection and placement-related injury must be discussed. Trials suggest trade-offs in pressure reduction and interventions, not universal device superiority. 8 9

PreserFlo study design and U.S. status

A randomized trial of 527 patients compared MicroShunt with trabeculectomy plus mitomycin C and was designed to test noninferiority. At 2 years, success was 50.6% versus 64.4%, with mean IOP 13.9 versus 10.7 mmHg. Interpret differences alongside definitions, complications and subsequent interventions; less invasive does not mean better for every patient. 8

Regulatory authorization is separate from efficacy. Glaukos’s 27 July 2026 announcement of completed enrollment in a new U.S.510(k) study is manufacturer information, not FDA clearance. Current U.S. authorization was not independently verified in this review. 17

Clinical evidence MicroShunt,2 y 8

Question and population: MicroShunt/trab+MMC;527 POAG patients;3:1 noninferiority trial

Result: Success 50.6%/64.4%,p=.005; IOP 13.9/10.7; medications 0.9/0.4; hypotony 30.9%/51.1%.

How should we read it?: Trial-specific success/hypotony definitions;2 years; cannot infer FDA rationale.

Clinical evidence XEN GPS,12 mo 9

Question and population: XEN/trab;POAG subgroup 130 treated patients(88/42)

Result: Composite success 61.4%/69.0%,p=.394; trab IOP reduction 2.8 mmHg greater; interventions 39.8%/76.2%.

How should we read it?: Subgroup,12 months, industry involvement; not equivalence or universal safety superiority.

Trabeculectomy and drainage tubes

Trabeculectomy creates a filtration route to the subconjunctival space. With antifibrotic wound-healing management, it can reach low pressures suitable for some advanced eyes. Success depends on healing and follow-up as well as the operation itself. TAGS supports discussing primary trabeculectomy in newly diagnosed advanced disease, while separating pressure/field benefit from quality of life. 5

Drainage tubes have an important role after previous surgery, with scarring or high filtration-failure risk. PTVT studied eyes without previous incisional surgery; TVT included previous cataract surgery and/or failed filtration. Their differing populations prevent a universal procedure ranking from these two studies. 6 7

Ahmed/Baerveldt comparisons show a trade-off: Baerveldt achieved lower pressure but more hypotony-related failure. This cannot be generalized to every tube design. Surgeon experience matters, but an undocumented explanation about training level cannot invalidate trial results. 13

Clinical evidence TAGS,5 y 5

Question and population: Primary trabeculectomy/medical treatment;453 new advanced OAG patients

Result: IOP 12.07/14.76 mmHg; adjusted difference−2.56(95%CI−3.80 to−1.32). VFQ-25 difference 1.01(−1.99 to 4.00),p=.51; better field preservation with surgery.

How should we read it?: Not proof of QoL superiority; treatment unmasked; advanced newly diagnosed population.

Clinical evidence PTVT,5 y 6

Question and population: Baerveldt 350/trab+MMC;242 eyes without prior incisional surgery

Result: Failure 42%/35%,p=.21; IOP 13.4/13.0; medications 2.2/1.3.

How should we read it?: Nonsignificant failure difference is not equivalence; differs from TVT.

Clinical evidence TVT,5 y 7

Question and population: Tube/trab+MMC; previous cataract surgery and/or failed trab

Result: Failure 29.8%/46.9%,p=.002.

How should we read it?: Not primary-surgery PTVT population; not a universal NVG rule.

Clinical evidence Ahmed/Baerveldt,5 y 13

Question and population: Pooled twoRCTs;514 eyes with failed/high-risk trab

Result: IOP 15.8/13.2; failure 49%/37%,p=.007; hypotony failure 0.4%/4.5%.

How should we read it?: Device/population-specific trade-off; not evidence for every tube including Paul.

Deep sclerectomy and cyclodestruction

Deep sclerectomy and viscocanalostomy preserve different tissue barriers from trabeculectomy; postoperative goniopuncture may be part of treatment. The older Cochrane review included five small, methodologically limited trials: it did not establish deep-sclerectomy equivalence to trabeculectomy. Cyclophotocoagulation reduces aqueous production; technique and visual potential affect selection. Inflammation, hypotony, vision loss and retreatment remain relevant; it is neither restricted categorically to blind eyes nor interchangeable with every drainage procedure. 1 14

06Apply the choice to the eye in front of you

Cataract, MIGS and target mismatch

Phaco alone or phaco+trabecular MIGS can suit selected early/moderate open-angle disease with a modest pressure/medication goal. A very low target or advanced progression requires consideration of a stronger pressure-lowering strategy. Stand-alone MIGS also exists. Phaco versus combined or staged bleb surgery depends on lens need, target, inflammation and conjunctival risk; there is no universal 6/12-month waiting rule or automatic 3-fold failure estimate. 1 10 11

Neovascular glaucoma and secondary disease

Rubeosis, angle neovascularization, high IOP and pain need urgent coordinated retinal/glaucoma care. Gonioscopy distinguishes open from synechially closed angle. Treat the ischemic retinal drive (PRP when feasible; anti-VEGF as a context-dependent adjunct) and pressure as related but separate goals. Anti-VEGF evidence suggests short-term benefit with low/very-low certainty and unclear durable benefit; it does not replace definitive ischemia/pressure treatment. Tube, trabeculectomy or cyclodestruction selection depends on inflammation, angle, visual potential, bleeding risk and prior surgery; 'tube always first' is unjustified. Uveitis and silicone-oil glaucoma likewise require mechanism-specific planning, not an almost-certain failure assumption or automatic iridotomy in every pseudophakic eye. 1 15

07Surgery does not end when the wound is closed

Aftercare, bleb healing and complications

Aftercare is part of surgery: assess IOP, vision, anterior-chamber depth, inflammation, wounds/bleb, implant position and cornea. Early low pressure requires identifying leak, overfiltration or other cause; high pressure requires identifying retained viscoelastic, hyphema, steroid response, obstruction or scarring. A shallow chamber, infection or vision deterioration needs prompt specialist assessment. Bleb massage, suture adjustment, needling and 5-FU/MMC are selected interventions, not routine instructions for every patient. Risks include hypotony maculopathy, choroidal complications, tube exposure and late bleb infection. Follow-up remains individualized and long term. 1 6 8 9

Drops, pilocarpine and viscoelastic

The drop plan addresses inflammation, infection risk and pressure dynamics according to the procedure and examination. A weekly 4-3-2-1 schedule must therefore not automatically combine antibiotics, steroids, pilocarpine and NSAIDs. The BANG/GATT trial stopped antibiotic after one week and tapered steroid separately: a study protocol, not a prescription for every patient. 12

Pilocarpine has selected uses after angle surgery, considering symptoms and contraindications; there is no established 'iris-memory' mechanism. Viscoelastic assists surgical chamber control, but retention can raise IOP. It is neither universally required to prevent hyphema nor a substitute for a secure wound. 1 12

08Guidelines and costs: keeping the decision grounded

The German MIGS guideline is DOG/BVA S 1, AWMF 045-029, datedApril 2025. Distinguish guideline level from randomized evidence for an individual device. 2

Costs, resource settings and big data

Clinical cost is more than the instrument price: facilities, staff, disposables, follow-up and repeat procedures contribute. A dollar price from a lecture cannot be transferred to another country without its date, procurement system and included items. In low-resource settings, including Syria, instrument simplicity is insufficient without sterilization, training, follow-up and complication-rescue pathways. 4 12

Registries and prediction models may inform patient selection and outcomes, but statistical association, reimbursement policy and validated clinical benefit are distinct. Algorithmic prediction of glaucoma progression still needs clinical validation before guiding surgery.

Limits of guideline verification

The German MIGS guidance is DOG/BVA S 1 AWMF 045-029(April 2025), not S 3. Its bibliographic record and erratum were checked, but detailed full text was not independently accessible. AAO 2025 PPP was located with the same extraction limitation. Therefore no precise recommendation is attributed to those unseen texts. EGS 6 full text was inspected; the study results below provide independent primary comparisons. IOP/medication outcomes are not automatically quality-of-life or sight-preservation benefits. Nonsignificant differences do not establish equivalence; subgroup, short follow-up, missing data and industry involvement affect confidence. 1 2 3

09Revise the reasoning, not just device names

What determines selection between filtration, tubes and MIGS?

Target pressure, stage and progression, disease mechanism, conjunctiva/prior surgery, lens, procedural risks, patient preferences and ability to attend follow-up.

Why can follow-up be part of the operation’s success?

Healing, pressure dynamics, inflammation and complications can require early intervention and influence the long-term result.

10References and original lectures

Numbers in the lecture link to the relevant source. Different studies do not constitute a direct comparison of every procedure.

  1. 1EGS 6 (2025), professional guideline; full text inspected, pp.22–24,163–164,192–202.
  2. 2DOG/BVA S1, AWMF045-029, April2025; bibliographic verification only; detailed full-text recommendations not independently retrieved. Erratum10.1007/s00347-025-02343-2.
  3. 3AAO POAG PPP2025; official record verified; full-text recommendations not extracted.
  4. 4LiGHT6-year RCT: initial SLT versus drops, treatment-naïve OAG/OHT.
  5. 5TAGS5-year RCT: primary trabeculectomy versus medication, newly diagnosed advanced OAG.
  6. 6PTVT5-year RCT: Baerveldt350 versus trabeculectomy+MMC, no previous incisional ocular surgery.
  7. 7TVT5-year RCT: tube versus trabeculectomy, previous cataract surgery and/or failed filtration.
  8. 8MicroShunt versus trabeculectomy, randomized noninferiority trial,2years.
  9. 9XEN45 GPS POAG subgroup, randomized study12months,2025.
  10. 10HORIZON randomized trial,5years: phaco+Hydrus versus phaco alone.
  11. 11iStent inject pivotal RCT,2years: phaco+two stents versus phaco alone.
  12. 12BANG versus GATT RCT,24months; published28September2026.
  13. 13Ahmed versus Baerveldt pooled randomized5-year evidence.
  14. 14Deep sclerectomy/viscocanalostomy versus trabeculectomy, Cochrane2014.
  15. 15Anti-VEGF for neovascular glaucoma, Cochrane2023.
  16. 16FDA CyPass recall, initiated28August2018; device-specific endothelial safety signal.
  17. 17Glaukos27July2026: enrollment completed in new U.S. PreserFlo510(k) pivotal study; company statement, not clearance.
  18. 18Aqueous outflow resistance, mechanistic review2019.
  19. 19Johnstone outflow mechanics, experimental ex-vivo study2016; supports mechanism, not clinical superiority.

Lectures underlying this topic

What does the operation aim to achieve?

The operation lowers pressure to protect remaining sight; drops or further procedures may still be needed. Attend scheduled checks and follow the individually prescribed drops and restrictions on rubbing, lifting and water exposure; duration is operation-specific. Severe pain, increasing redness, discharge or sudden visual loss requires immediate contact with the surgical team/emergency eye service. Late infection can occur months or years after bleb surgery. Educational information does not replace examination or individualized treatment.

When should you seek help immediately?

For severe pain, increasing redness, discharge or sudden vision loss, contact the surgical team or emergency eye service immediately.